Roflumilast as add-on Therapy in Early Cases of ARDS

"1. Roflumilast 500 mcg daily for up to 28 days~2. Total follow up time will be 28 days.~3. Proinflammatory parameters will be assessed at baseline, day 7, day 14, and at the end of treatment.~4. Roflumilast will be combined with standard of care for ARDS.~5. During hospitalization, clinical and laboratory data will be recorded daily in the medical history of the patient and in data collection table of the study.~6. During hospitalization, adverse drug reaction will be monitored clinically and by laboratory tests.~7. In case of an adverse effect or a need to discontinue the treatment, roflumilast should be suspended."

Placebo (identical to roflumilast dosage form) will be used for placebo-comparator group.